ATLANTA, GA – Georgia Tech startup SpherIngenics has received a two-year $730,000 federal grant to develop microbead technology that produces protective capsules for the delivery of cell-based therapies.
With the new funding, from the U.S. Department of Defense, the researchers plan to examine whether delivering microbeads full of stem cells can enhance cartilage repair and regeneration of craniofacial defects in an animal model.
SpherIngenic’s ultimate goal is to commercialize the microbead technology for use in hospitals and by cell therapy companies.
Cell-based therapies have yet to reach their full potential in repairing damaged tissue because of the hostile environment the cells face once injected into the body. A patient’s inflammatory response normally causes the majority of these therapeutic cells to die or migrate away from the area in need of repair.
“When damaged tissue is being repaired by a cell-based therapy, our microbead technology ensures that cells travel to and remain in the targeted area while maintaining continued viability,” SpherIngenics CEO Franklin Bost noted. “This technology has the potential to reduce the cost of treatment by eliminating the need for multiple therapeutic procedures.”